U.S., March 28 -- ClinicalTrials.gov registry received information related to the study (NCT06897527) titled 'A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC)' on March 20.
Brief Summary: The goal of this study is to evaluate the safety profile of dostarlimab in Indian adults with recurrent or advanced endometrial cancer.
Study Start Date: April 17
Study Type: INTERVENTIONAL
Condition:
Neoplasms, Endometrial
Intervention:
DRUG: Dostarlimab
Dostarlimab will be administered.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: GlaxoSmithKline
Published by HT Digital Content Services with permission from Health Daily Digest....